TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo November 12, 2020 Rudy Mazzocchi President and Chief Executive Officer Agentix Corp. 32932 Pacific Coast Highway, #14-254 Dana Point, CA 92629 Re: Agentix Corp. Post-effective Amendment No. 1 to Registration Statement on Form S-1 Filed November 4, 2020 File No. 333-248589 Dear Mr. Mazzocchi: We have reviewed your post-effective amendment and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Post-effective Amendment No. 1 to Registration Statement on Form S-1 filed November 4, 2020 General 1. Please be advised that pursuant to Rule 8-08 of Regulation S-X, you were required to include audited financial statements for the fiscal year ended August 31, 2020 in this Post- effective Amendment. In this regard, you do not report income from continuing operations attributable to the registrant before taxes in either fiscal year 2019 or 2018 (page F-14), and therefore, you do not satisfy the requirement of Rule 8-08(b)(3) of Regulation S-X. As such, you are required to update your financial statements in registration statements filed after 45 days but within 90 days of the year ended August 31, 2020. Please revise your registration statement to update the financial statements. Rudy Mazzocchi FirstName LastNameRudy Mazzocchi Agentix Corp. Comapany 12, November NameAgentix 2020 Corp. November Page 2 12, 2020 Page 2 FirstName LastName We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 or Mary Beth Breslin at 202-551-3625 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey M. Quick, Esq.